Cargando…

Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment

Clinical trials have confirmed that chimeric antigen receptor (CAR) T cell therapies are revolutionizing approaches for treating several relapsed or refractory hematological tumors. Cytokine release syndrome (CRS) is an adverse event with high incidence during CAR-T treatment. A further understandin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Zhiling, Zhang, Huanxin, Cao, Jiang, Zhang, Cheng, Liu, Hui, Huang, Hongming, Cheng, Hai, Qiao, Jianlin, Wang, Ying, Wang, Yan, Gao, Lei, Shi, Ming, Sang, Wei, Zhu, Feng, Li, Depeng, Sun, Haiying, Wu, Qingyun, Qi, Yuekun, Li, Hujun, Wang, Xiangmin, Li, Zhenyu, Liu, Hong, Zheng, Junnian, Qian, Wenbin, Zhang, Xi, Xu, Kailin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940756/ https://www.ncbi.nlm.nih.gov/pubmed/33708205 http://dx.doi.org/10.3389/fimmu.2021.611366

Ejemplares similares

An Analysis of Cardiac Disorders Associated With Chimeric Antigen Receptor T Cell Therapy in 126 Patients: A Single-Centre Retrospective Study
por: Qi, Kunming, et al.
Publicado: (2021)

Anti–G Protein–Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial
por: Xia, Jieyun, et al.
Publicado: (2023)

Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma
por: Zhang, Huanxin, et al.
Publicado: (2022)

Prognostic value of prelymphodepletion absolute lymphocyte counts in relapsed/refractory diffuse large B-cell lymphoma patients treated with chimeric antigen receptor T cells
por: Lu, Yanyan, et al.
Publicado: (2023)

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021)

Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed/refractory multiple myeloma treated with CAR-T therapy
por: Wang, Xue, et al.
Publicado: (2022)

Advantages of digital PCR in the detection of low abundance BCR-ABL1 gene in patients with chronic myeloid leukemia
por: Yan, Zhiling, et al.
Publicado: (2019)

Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma
por: Sang, Wei, et al.
Publicado: (2022)

Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
por: Sang, Wei, et al.
Publicado: (2020)

Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma
por: Wang, Xue, et al.
Publicado: (2022)

Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia
por: Hong, Fei, et al.
Publicado: (2021)

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
por: Li, Hujun, et al.
Publicado: (2022)

A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells
por: Liu, Yang, et al.
Publicado: (2023)

Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy
por: Chen, Wei, et al.
Publicado: (2021)

TIRC7 inhibits Th1 cells by upregulating the expression of CTLA-4 and STAT3 in mice with acute graft-versus-host disease
por: Zhu, Feng, et al.
Publicado: (2020)

High expression of miR-363 predicts poor prognosis and guides treatment selection in acute myeloid leukemia
por: Zhang, Huihui, et al.
Publicado: (2019)

MALT1 Inhibition as a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia by Blocking Notch1-Induced NF-κB Activation
por: Wang, Rong, et al.
Publicado: (2020)

Macrophages ameliorate bone marrow inflammatory injury and promote hematopoiesis in mice following hematopoietic stem cell transplantation
por: Qiao, Jianlin, et al.
Publicado: (2018)

High expression of CPNE3 predicts adverse prognosis in acute myeloid leukemia
por: Fu, Lin, et al.
Publicado: (2017)

Tetraploid embryonic stem cells can contribute to the development of chimeric fetuses and chimeric extraembryonic tissues
por: Wen, Bingqiang, et al.
Publicado: (2017)

Virus-Like Particles of Chimeric Recombinant Porcine Circovirus Type 2 as Antigen Vehicle Carrying Foreign Epitopes
por: Zhang, Huawei, et al.
Publicado: (2014)

Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice
por: Zhang, Qing, et al.
Publicado: (2016)

Platycodin D inhibits platelet function and thrombus formation through inducing internalization of platelet glycoprotein receptors
por: Luo, Qi, et al.
Publicado: (2018)

NLRP3 regulates platelet integrin αIIbβ3 outside-in signaling, hemostasis and arterial thrombosis
por: Qiao, Jianlin, et al.
Publicado: (2018)

The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma
por: Sun, Xiaoyang, et al.
Publicado: (2019)

Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy
por: Mei, Heng, et al.
Publicado: (2022)

The role of DNA methylation in the maintenance of phenotypic variation induced by grafting chimerism in Brassica
por: Liu, Ke, et al.
Publicado: (2023)

Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy
por: Zhang, Lina, et al.
Publicado: (2021)

An absence of platelet activation following thalidomide treatment in vitro or in vivo
por: Qiao, Jianlin, et al.
Publicado: (2017)

MiR-425 expression profiling in acute myeloid leukemia might guide the treatment choice between allogeneic transplantation and chemotherapy
por: Yang, Chen, et al.
Publicado: (2018)

Could cytokine release syndrome induce acute myelofibrosis in CD19 chimeric antigen receptor T cells therapy?
por: Lai, Xun, et al.
Publicado: (2020)

Cytokine Concentrations in Aqueous Humor of Eyes With Circumscribed Choroidal Hemangioma
por: Liu, Kailin, et al.
Publicado: (2022)

Matrine Impairs Platelet Function and Thrombosis and Inhibits ROS Production
por: Zhang, Sixuan, et al.
Publicado: (2021)

Identification of a novel c-Myc inhibitor with antitumor effects on multiple myeloma cells
por: Yao, Ruosi, et al.
Publicado: (2018)

Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors
por: Su, Yinghan, et al.
Publicado: (2022)

Emission Reduction Benefits and Economic Benefits of China's Pilot Policy on Carbon Emission Trading System
por: Wang, Zhijia, et al.
Publicado: (2022)

(18)F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma
por: Kong, Ziren, et al.
Publicado: (2019)

Cytokine release syndrome complicated with rhabdomyolysis after chimeric antigen receptor T-cell therapy: A case report
por: Zhang, Lan, et al.
Publicado: (2022)

Generation and Application of Inducible Chimeric RNA ASTN2-PAPPA(as) Knockin Mouse Model
por: Luo, Yichen, et al.
Publicado: (2022)

Inflammatory cytokine profiles in eyes with primary angle-closure glaucoma
por: Wang, Yayi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m3vas2v0jo52v7l47fm31h0v32